Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4%

CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 4,800,000 shares, a decrease of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is presently 3.9 days.

Institutional Trading of CytomX Therapeutics

Several large investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. lifted its holdings in CytomX Therapeutics by 32.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock worth $1,940,000 after purchasing an additional 405,669 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 16,359 shares during the period. Congress Park Capital LLC lifted its stake in shares of CytomX Therapeutics by 5.4% in the third quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock worth $1,435,000 after buying an additional 62,788 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after buying an additional 34,032 shares during the period. Finally, Sei Investments Co. acquired a new position in CytomX Therapeutics in the 2nd quarter valued at $467,000. Institutional investors own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Trading Down 0.8 %

NASDAQ CTMX traded down $0.01 during trading on Friday, reaching $0.84. The company’s stock had a trading volume of 620,234 shares, compared to its average volume of 992,394. The stock has a market capitalization of $65.74 million, a PE ratio of 4.94 and a beta of 1.03. CytomX Therapeutics has a 1-year low of $0.79 and a 1-year high of $5.85. The business has a 50-day moving average price of $1.04 and a 200-day moving average price of $1.15.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.23. The business had revenue of $33.43 million during the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter in the previous year, the business earned $0.04 EPS. As a group, analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.